25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy.
Acta Myol
; 39(4): 336-344, 2020 Dec.
Article
en En
| MEDLINE
| ID: mdl-33458589
ABSTRACT
The new era of advanced therapies has influenced and changed the views and perspectives of a neuromuscular disease such as spinal muscular atrophy (SMA). Being an autosomal recessive motor neuron disorder, characterized by different degrees of muscle weakness, after 25 years of the discovery of the determinant and modifier genes (SMN1 and SMN2, respectively) three SMN-dependent specific therapies are already approved by FDA (two by EMA), so that worldwide patients are currently under clinical investigation and treatment. This success was the combined effort mainly of patients and families, physician and researchers, advocacy groups and several Institutions together with the support of pharmaceutical companies. Progression trajectories, phenotypes, follow-up and care of the patients are continously evolving. Clinical investigations are currently demonstrating that early diagnosis and intervention are essential for better and more effective response to treatment, consistently improving prognosis. This scenario has created the need for awareness, early diagnosis and even implementation of of newborn screening programs. New views and perspectives of patient and family expectations, genetic counselling and multidisciplinary care a truly Copernican revolution in neuromuscular and genetic diseases.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Atrofia Muscular Espinal
/
Proteína 1 para la Supervivencia de la Neurona Motora
Tipo de estudio:
Prognostic_studies
/
Screening_studies
Límite:
Humans
/
Newborn
Idioma:
En
Revista:
Acta Myol
Asunto de la revista:
CARDIOLOGIA
/
FISIOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia